Miriam Jacob, MD
Cardiovascular Disease · Cleveland, OHNPI 1477587780
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 76.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $379 and has fallen 69.6% since, to $115 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in OH, where the typical reported total is $1,347.
Across 13 payments — averaging $54.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$543
- Alnylam Pharmaceuticals Inc.$115
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$36
- Merck$19
Across 66 payments — averaging $3647.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$176K
- United Therapeutics Corporation$65K
What the payments were for
- Food & beverage$714100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $543 |
| Alnylam Pharmaceuticals Inc. | 1 | $115 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $36 |
| Merck | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$714 in reported general payments places this provider in the 35th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 31 | $698,749 |
| UptraviSelexipag | 17 | $585,938 |
| Ambrisentan | 69 | $277,528 |
| EntrestoSacubitril/Valsartan | 225 | $277,409 |
| JardianceEmpagliflozin | 207 | $238,135 |
| LetairisAmbrisentan | 18 | $234,956 |
| EliquisApixaban | 160 | $177,935 |
| AdempasRiociguat | 13 | $169,310 |
| FarxigaDapagliflozin Propanediol | 18 | $24,295 |
| XareltoRivaroxaban | 22 | $22,953 |
| Sildenafil Citrate | 44 | $11,443 |
| Repatha SureclickEvolocumab | 14 | $8,585 |
| CorlanorIvabradine Hcl | 12 | $7,587 |
| Metoprolol Succinate | 332 | $6,395 |
| Tadalafil | 28 | $5,146 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Cleveland
- Guilherme AttizzaniCleveland$1.3M
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Mazen HannaCleveland$208K
- Brian HoitCleveland$207K
- Steven NissenCleveland$149K
- Daniel CantillonCleveland$140K
- Serge HarbCleveland$134K
- Wael JaberCleveland$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.